Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension

被引：0
|
作者：
ZH Israili
机构：
[1] Emory University School of Medicine,
来源：
Journal of Human Hypertension | 2000年 / 14卷
关键词：
angiotensin receptor blockers; candesartan; eprosartan; irbesartan; losartan; telmisartan; valsartan; pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Angiotensin II receptor blockers (ARBs) represent a new class of effective and well tolerated orally active antihypertensive agents. Recent clinical trials have shown the added benefits of ARBs in hypertensive patients (reduction in left ventricular hypertrophy, improvement in diastolic function, decrease in ventricular arrhythmias, reduction in microalbuminuria, and improvement in renal function), and cardioprotective effect in patients with heart failure. Several large long-term studies are in progress to assess the beneficial effects of ARBs on cardiac hypertrophy, renal function, and cardiovascular and cerebrovascular morbidity and mortality in hypertensive patients with or without diabetes mellitus, and the value of these drugs in patients with heart disease and diabetic nephropathy.
引用
收藏
页码：S73 / S86
相关论文
共 50 条
12345